SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (6023)2/1/1999 10:27:00 AM
From: Oliver & Co   of 6136
 
Some AIDS Patients Restored by Drugs Suddenly Decline"
Wall Street Journal (www.wsj.com) (02/01/99) P. B1; Tanouye,
Elyse
Despite the initial success of AIDS drugs to reduce viral levels
to below detectable levels in many patients, researchers say an
increasing number of patients who have benefited from the drugs
for several years are developing resistance to the drugs and
experiencing an increase in viral levels. Indeed, findings set
to be presented at an AIDS conference in Chicago show that only
about two-thirds of patients using a drug regimen including
Merck's Crixivan had very low levels of virus copies in their
blood after three years, compared with about 90 percent of
patients earlier in the study. Researchers have said they did
not expect the drugs to be effective forever, but they cannot
explain why some patients are suddenly not responding. One
theory suggests that the low viral levels in the body trick the
immune system into thinking the threat is gone and that the body
stops fighting the virus.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News